Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis

7 Dec 2020

Abstract excerpt

Abstract Background Human leukocyte antigen class 1 (HLA-1)–dependent immune activity is linked to autoimmune diseases. HLA-1–dependent CD8+ T cells are required for immune checkpoint blockade antitumor activity. It is unknown if HLA-1 genotype is predictive of toxicity to immune checkpoint blockade. Methods Patients with advanced solid tumors stratified into 5 cohorts received single agent pembrolizumab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33554038
DOI: 10.1093/jncics/pkaa115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 AnalysisPMID 33554038Read ↗

HLA Genotype is Associated With Clinical Outcomes to anti-PD1 Therapy in Advanced MelanomaSemantic proximity Read ↗

Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.Semantic proximity Read ↗

HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.Semantic proximity Read ↗

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanomaSemantic proximity Read ↗

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.Semantic proximity Read ↗

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line therapySemantic proximity Read ↗

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approachSemantic proximity Read ↗

Association between germ-line HLA and immune-related adverse eventsSemantic proximity Read ↗

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.Semantic proximity Read ↗

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancerSemantic proximity Read ↗

MHC-I genotype and tumor mutational burden predict response to immunotherapy.Semantic proximity Read ↗

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.